Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze CRSP stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate CRSP investment potential.

What is CRSP stock price today?

Get real-time CRSP stock price, historical data, and price charts on Financhill. Track CRSP performance with our advanced analysis tools.

Is CRSP a good investment?

Evaluate CRSP investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy CRSP stock?

To buy CRSP stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of CRSP?

View detailed market capitalization data and company valuation metrics for CRSP on our comprehensive analysis page.

What is the P/E ratio of CRSP?

Use our fundamental analysis tools to view CRSP P/E ratio and compare valuation metrics with industry peers.

What are CRSP earnings?

View CRSP earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

CRISPR Therapeutics AG 10K Form

Buy

CRSP
CRISPR Therapeutics AG

Last Price:

$57.80

Seasonality Move:

3.35%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-06	10Q	CRSP/CRISPR Therapeutics AG Quarterly
2023-08-07	10Q	CRSP/CRISPR Therapeutics AG Quarterly
2023-05-08	10Q	CRSP/CRISPR Therapeutics AG Quarterly
2022-11-01	10Q	CRSP/CRISPR Therapeutics AG Quarterly
2022-08-08	10Q	CRSP/CRISPR Therapeutics AG Quarterly
2022-05-09	10Q	CRSP/CRISPR Therapeutics AG Quarterly

Receive CRSP News And Ratings

See the #1 stock for the next 7 days that we like better than CRSP

CRSP Financial Statistics

Sales & Book Value

Annual Sales:	$3.5M
Cash Flow:	$-93.1M
Price / Cash Flow:	0
Annual Sales:	$20.04
Price / Book:	3

Profitability

EPS (TTM):	-6.51450
Net Income (TTM):	$-581.6M
Gross Margin:	$-229.4M
Return on Equity:	-31.24%
Return on Assets:	-26.56%

CRISPR Therapeutics AG Earnings Forecast

Key CRISPR Therapeutics AG Financial Ratios

The Gross Profit Margin over the past 5 years for CRSP is -6,537.01%.
The Selling, General & Administrative Expenses for CRSP have been equal to 2,095.21% of Gross Profit Margin.
The Research & Development expenses have been 7,559.17% of Revenue.
The Net Earning history of CRSP is -16,569.77% of Total Revenues.
Per Share Earnings over the last 12 years have been positive in 4 years.

CRISPR Therapeutics AG Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	CRSP
CUSIP:	H17182
Website:	crisprtx.com

Debt

Debt-to-Equity Ratio:	0.11
Current Ratio:	13.32
Quick Ratio:	13.3

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	0

CRSP Technical Analysis vs Fundamental Analysis

Buy

CRISPR Therapeutics AG (CRSP) is a Buy

Is CRISPR Therapeutics AG a Buy or a Sell?

CRISPR Therapeutics AG stock is rated a Buy

The current CRISPR Therapeutics AG [CRSP] share price is $60.00. The Score for CRSP is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.